60 Degrees Pharmaceuticals Announces Date for Hospitalized Babesiosis Study Interim Data Release and Key Opinion Leader ...
Interim analysis results from clinical study evaluating tafenoquine in severe babesiosis (NCT06207370) to be disclosed on October 6, 2026. Key Opinion Leader investor webinar scheduled for October 6, 2026, featuring leading babesiosis experts Dr. Peter …